Responses

Download PDFPDF

Hodgkin's lymphoma: the pathologist's viewpoint
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    How do we define Hodgkin disease?

    Dear Editor

    It is a pleasure to read Professor Pileri’s recent article on Hodgkin disease (HD).

    Reflecting back, it took a long time and a lot of effort to identify the cell of origin of the RS cell, which in 98% of cases is a follicular center B-cell. It took a lot more time to recognize that in 2% of classical HD (cHD) cases the RS cells are actually of T-cell origin. Surprisingly, and rightly so (in...

    Show More
    Conflict of Interest:
    None declared.